SLC5A2 and diabetes mellitus: Complementary therapy based on monoclonal antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9), the SGLT-2 (sodium-glucose cotransporter-2) inhibitors, GLP-1 RAs (glucagon-like peptide-1 receptor agonists), and novel therapy based on RNA therapeutics and targeting the RAGE (receptor for advanced glycation end-products) can provide cardioprotection in diabetes [87].